Related Experiment Videos
Antisense inhibition of ras p21 expression that is sensitive to a point mutation
E H Chang1, P S Miller, C Cushman
1Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Abstract:
Many genetic disorders result from a single point mutation, and many tumor oncogenes have been found to be altered by a point mutation. The ability to inhibit selectively the expression of the mutated form of a protein without affecting its normal counterpart is central to many therapeutic strategies, since the normal protein may serve indispensable functions. Antisense oligonucleoside methylphosphonates and their psoralen derivatives directed at either normal human Ha-ras p21 or ras p21 that is mutated at a single base in codon 61 have been examined for their efficacy and specificity as inhibitors of p21 expression. Mixed cultures of cells expressing both forms of p21 were treated with the antisense oligomer complementary to the normal p21 or with the antisense oligomer complementary to the point-mutated p21. Each of the antisense oligomers specifically inhibited expression of only the form of ras p21 to which it was completely complementary and left the other form of p21 virtually unaffected.
Insights
Antisense oligonucleotides can selectively inhibit mutated ras p21 expression without affecting normal Ha-ras p21. This targeted approach offers potential for treating genetic disorders and cancers caused by point mutations.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Single point mutations are implicated in numerous genetic disorders and the alteration of tumor oncogenes.
- Selective inhibition of mutated proteins is crucial for therapeutic strategies, as normal protein counterparts often have essential functions.
Purpose of the Study:
- To evaluate the efficacy and specificity of antisense oligonucleoside methylphosphonates and their psoralen derivatives in inhibiting the expression of normal and mutated forms of human Ha-ras p21.
Main Methods:
- Antisense oligomers complementary to either normal human Ha-ras p21 or a point-mutated ras p21 (codon 61) were designed.
- Mixed cell cultures expressing both forms of p21 were treated with these specific antisense oligomers.
Main Results:
- Each antisense oligomer demonstrated high specificity, inhibiting only the expression of the ras p21 form to which it was complementary.
- The expression of the non-targeted ras p21 form remained largely unaffected by the treatment.
Conclusions:
- Antisense oligonucleotides can be precisely designed to selectively target and inhibit the expression of mutated ras p21, leaving the normal form intact.
- This high specificity highlights the therapeutic potential of antisense technology for conditions arising from single point mutations, such as genetic disorders and oncogene alterations.